Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma
- Jacquelot, N; Seillet, C; Wang, M; Pizzolla, A; Liao, Y; Hediyeh-Zadeh, S; Grisaru-Tal, S; Louis, C; Huang, Q; Schreuder, J; Souza-Fonseca-Guimaraes, F; de Graaf, CA; Thia, K; Macdonald, S; Camilleri, M; Luong, K; Zhang, S; Chopin, M; Molden-Hauer, T; Nutt, SL; Umansky, V; Ciric, B; Groom, JR; Foster, PS; Hansbro, PM; McKenzie, ANJ; Gray, DHD; Behren, A; Cebon, J; Vivier, E; Wicks, IP; Trapani, JA; Munitz, A; Davis, MJ; Shi, W; Neeson, PJ; Belz, GT;
- Journal Title
- Nature Immunology
- Group 2 innate lymphoid cells (ILC2s) are essential to maintain tissue homeostasis. In cancer, ILC2s can harbor both pro-tumorigenic and anti-tumorigenic functions, but we know little about their underlying mechanisms or whether they could be clinically relevant or targeted to improve patient outcomes. Here, we found that high ILC2 infiltration in human melanoma was associated with a good clinical prognosis. ILC2s are critical producers of the cytokine granulocyte-macrophage colony-stimulating factor, which coordinates the recruitment and activation of eosinophils to enhance antitumor responses. Tumor-infiltrating ILC2s expressed programmed cell death protein-1, which limited their intratumoral accumulation, proliferation and antitumor effector functions. This inhibition could be overcome in vivo by combining interleukin-33-driven ILC2 activation with programmed cell death protein-1 blockade to significantly increase antitumor responses. Together, our results identified ILC2s as a critical immune cell type involved in melanoma immunity and revealed a potential synergistic approach to harness ILC2 function for antitumor immunotherapies.
- WEHI Research Division(s)
- Immunology; Bioinformatics; Blood Cells And Blood Cancer; Inflammation
- PubMed ID
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2021-06-10 11:47:05Last Modified: 2021-06-10 12:09:40